, a clinical diagnostic and blood screening products maker, said Thursday it settled patent disputes with
Under the agreement, Gen-Probe will withdraw its patent litigation against Bayer and will grant Bayer immunity from suit with respect to all existing and future Gen-Probe patents for all of Bayer's current nucleic acid diagnostic products.
In addition, future Bayer products will be immune from suit under four specified Gen-Probe patent families.
Bayer will grant Gen-Probe immunity from suit under certain Bayer patents with respect to Gen-Probe's current TIGRIS instrument and future instruments. Additionally Bayer will pay Gen-Probe certain lump sum royalties over the next 18 months. Bayer, however, will not be required to reimburse Gen-Probe $2.0 million for legal expenses.
"We are pleased to have concluded our legal disputes with Bayer, and to gain additional revenue that will enable us to invest in commercially attractive, previously unfunded development projects that will drive future growth," San Diego-based Gen-Probe said.
This story was created through a joint venture between TheStreet.com and IRIS.